Search Results

Kawthar Belkacemi, Philippe Rondard, Jean-Philippe Pin, and Laurent Prézeau, for their research on Heterodimers the tumor microenvironment in cancer progression and therapy Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer

Namkung et al. 2016), and avoid depletion may also contribute to its ability to efficiently scavenge T. Gilliland et. al 2013). Scavenging may allow cells to continuously migrate by remaining responsive to chemokines (S. Hansell et al. 2011); and it may interfere with other chemokine receptors which share the ligands and Aiello et. al 2010) which may ultimately compete with receptor antagonists, thereby decreasing the efficacy

authors set out to investigate GalNAc-Ts candidates involved in CCR5 O-glycosylation with CHO GalNAc-T GalNAc-Ts, GalNAc-T1 was shown to be the most likely candidate for directly glycosylating CCR5 although T11 may although direct effects of O-glycosylation removal are ruled out it is possible that indirect effects may understanding on the dynamics and biological relevance of these PTMs in the chemokine receptor system which may

cancer, where tumors hijack the chemokine system to provide growth and survival signals, establish and maintain The therapeutic approaches mainly include small molecule inhibitors, as well as monoclonal antibodies for the treatment of mycosis fungoides or Sézary syndrome in adults which are subtypes of cutaneous T-cell inappropriate target selection and insufficient dosing of chemokine receptor antagonists in vivo might be the main

receptors induces IFN-γ but suppresses IL-2 production by inhibiting activation of pAKT pathways in primary T

GPCRs in Immunology and Oncology The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer

Kenakin, T. and A.

between GPCRs and β-arrestins, paving the way for capturing challenging protein complexes (Böttke, T. β-arrestin interaction partners remain elusive, and certain effector proteins with overlapping sites may In certain cancer types, only one β-arrestin isoform's expression may be altered, while the other remains

Antibody batch-to-batch differences Antibodies from different lots may show different characteristics Specificity issues Some antibodies bind to shared epitopes across different proteins, which may lead Fluorescent ligands  provide some key advantages  that may solve these issues: 1.       interactions and signaling pathways. -            Biased signaling detection Biased pharmacophores may Charlottesville (VA): University of Virginia; [cited 2025 May 16].

What remains may be a much smaller, but far more meaningful, difference. A low-efficacy agonist tested in a low-sensitivity system may show no visible response—even at concentrations This has direct implications: A “non-selective” compound may simply be under-detected. A “silent” ligand may be system-limited. A development decision may hinge on assay sensitivity rather than molecular behavior.

maximal signal Normalizing agonist responses to a common reference window Accepting that maximal response may A ligand may show identical EC₅₀ values in two assays while engaging receptors through very different Two compounds with identical potency may behave very differently in vivo if one remains bound longer. Even potent inhibitors may fail simply because they never reach sufficient concentration in vivo .

A ligand that occupies the orthosteric binding site and displaces a radiolabeled probe may appear equivalent complementary assay formats provides the needed mechanistic depth to define the functional selectivity  that may A compound that appears equivalent to a reference agonist in a cAMP assay may diverge sharply in a β Biased agonism  adds another layer: a pathway bias observed in a recombinant cell line may not hold in

This lecture is a roadmap for understanding why two drugs with similar affinity may behave completely If you’re still treating GPCRs as passive targets, your screening filters may be blind to key liabilities Ligands may take hours to equilibrate , even when they look potent on paper.

You have until May 3rd, 2023 to register. Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between May 9th and May 30th, 2024, from 10 am to 12 pm EDT. 1, 2024 | FREE ASPET Virtual Award Lecture Series May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition June 2

Operationalizing Allosteric Signatures Early workflows often rely on rapid “one-way” experiments — screens that may Yet rare adverse effects may only emerge after large-scale exposure, and selectivity must still be demonstrated What appears settled under one experimental condition may require refinement under another. Sustained exposure to disciplined mechanistic reasoning The value lies not in a single explanation, but in maintaining

Kenakin challenges this assumption and shows that what you’re seeing may reflect something entirely different In many systems, a ligand may appear to bind with very high affinity when it facilitates formation of

Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between May 9th and May 30th, 2024, from 10 am to 12 pm EDT. conferences Montana Molecular is joining the BioTools Innovator program GPCR Events, Meetings, and Webinars May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS

Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between May 9th and May 30th, 2024, from 10 am to 12 pm EDT. of Partnered Schizophrenia Candidate NBI-1117568 GPCR Events, Meetings, and Webinars NEW April 17 – May 1, 2024 | FREE ASPET Virtual Award Lecture Series May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS Europe 2024 Conference and Exhibition June 2

Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between May 9th and May 30th, 2024, from 10 am to 12 pm EDT. illuminates pathways used by dopamine, opioids and other neuronal signals GPCR Events, Meetings, and Webinars May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS

From autoimmune disorders  to long COVID , we may be seeing just the tip of the iceberg.

But plotting on a logarithmic axis exposes how far the system may actually be from true saturation. After a ligand binds, the receptor may transition further—often via G protein coupling. You may see: Early stopping → potency distortions Different stopping times → incomparable datasets Curve

Biased agonism introduces additional layers where one pathway may mimic “reflex-like” counterbalancing A compound may appear benign with one substrate and problematic with another. Lower-affinity alternatives may produce deeper, more therapeutically relevant coverage.

Recent studies suggest that class B1 GPCRs can form both homodimers and heterodimers, which may play These dimeric interactions may contribute to the phenomenon of biased agonism, where ligands produce dimerization is critical for regulating GPCR function, particularly with respect to biased agonism, which may receptor's extracellular domain (ECD), facilitating the partial disengagement of the peptide while maintaining

Samuel Hoare on Advanced data analysis for GPCR pharmacology, which will be held on Thursdays between May 9th and May 30th, 2024, from 10 am to 12 pm EDT. Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS

GPCR University Save the date for our upcoming workshop, starting May 9th, 2024, featuring Dr.  3D Protein Structure Prediction of Large, Complex Protein Structures Newly discovered adhesion GPCR mayo Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS

GPCR Symposium on GPCR Activation and Signaling, May 19th, 2023. Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics (May (May 22 - 26, 2023) 2nd LEAPS Meets Life Sciences Conference. (May 14 - 19, 2023) 8th and final ERNEST Meeting in Crete. (May 3 - 7, 2023).

Mark your calendar; we’re planning a workshop for May 2024 with Dr. Sam Hoare as our instructor. Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual Meeting May 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS

Procrastination may seem tempting, but tackling your work incrementally will save time and reduce stress The road may be long, and challenges will test your resolve, but every small victory along the way shapes

GPCR Symposium on GPCR Activation and Signaling on May 19th, 2023. Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics (May (May 22 - 26, 2023) 2nd LEAPS Meets Life Sciences Conference. (May 14 - 19, 2023) NEW PEGS Boston (May 15 - 19, 2023) 8th and final ERNEST Meeting in Crete. (May 3 - 7, 2023). The Illuminating the Understudied Druggable Proteome Conference.

Hello GPCR Colleagues and Collaborators, We’re diving into May with serious momentum.